OrthoPediatrics Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KIDS?
Source: seekingalpha
- Significant Revenue Growth: In Q1 2026, OrthoPediatrics reported worldwide revenue of $59.4 million, reflecting a 13% increase year-over-year, despite a temporary decline due to weather disruptions in January and February, with a rebound in March indicating resilient market demand.
- Improved Adjusted EBITDA: The adjusted EBITDA for the first quarter was $2.2 million, a substantial improvement from a loss of $0.4 million in Q1 2025, showcasing the company's significant enhancements in cost control and operational efficiency, which are expected to lay a solid foundation for future profitability.
- Optimized Financing Structure: On March 31, the company amended its existing credit agreement to add a $20 million delayed draw term loan facility, which will help maintain liquidity and avoid dilution, with interest payments only due until maturity in 2029.
- Upgraded 2026 Performance Outlook: Management raised the 2026 revenue guidance to a range of $263 million to $267 million, with an expected adjusted EBITDA of approximately $25 million, emphasizing the company's strategic positioning and market expansion potential within the innovation super cycle.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KIDS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KIDS
Wall Street analysts forecast KIDS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.640
Low
20.00
Averages
23.00
High
26.00
Current: 14.640
Low
20.00
Averages
23.00
High
26.00
About KIDS
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OrthoPediatrics Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: In Q1 2026, OrthoPediatrics reported worldwide revenue of $59.4 million, reflecting a 13% increase year-over-year, despite a temporary decline due to weather disruptions in January and February, with a rebound in March indicating resilient market demand.
- Improved Adjusted EBITDA: The adjusted EBITDA for the first quarter was $2.2 million, a substantial improvement from a loss of $0.4 million in Q1 2025, showcasing the company's significant enhancements in cost control and operational efficiency, which are expected to lay a solid foundation for future profitability.
- Optimized Financing Structure: On March 31, the company amended its existing credit agreement to add a $20 million delayed draw term loan facility, which will help maintain liquidity and avoid dilution, with interest payments only due until maturity in 2029.
- Upgraded 2026 Performance Outlook: Management raised the 2026 revenue guidance to a range of $263 million to $267 million, with an expected adjusted EBITDA of approximately $25 million, emphasizing the company's strategic positioning and market expansion potential within the innovation super cycle.
See More
OrthoPediatrics (KIDS) Q1 2026 Earnings Transcript
See More
OrthoPediatrics Reports Strong Q4 2025 Earnings with Positive Cash Flow
- Significant Revenue Growth: OrthoPediatrics reported worldwide revenue of $61.6 million for Q4 2025, reflecting a 17% year-over-year increase, with U.S. revenue at $48.6 million and international revenue at $13.0 million, demonstrating strong performance across trauma, deformity, and scoliosis segments, thereby solidifying its market position.
- First Positive Free Cash Flow: The company achieved $10 million in free cash flow during Q4 2025, marking its first quarter of positive cash flow in history, which indicates a significant improvement in operational efficiency and provides funding support for future investments and expansions.
- Optimistic 2026 Outlook: Management reiterated its revenue guidance for 2026 at $262 million to $266 million, projecting an annual growth rate of 11% to 13%, while also expecting approximately $25 million in adjusted EBITDA, reflecting confidence in sustained profitability and growth.
- Launch of Innovation Cycle: The company commenced what it believes to be the most substantial series of product launches in its history in 2025, including the 3P Hip and VerteGlide, which is expected to initiate a multi-year super cycle of product innovation, laying a foundation for future growth and expanding market share.
See More
OrthoPediatrics Q4 Earnings Report Analysis
- Earnings Performance: OrthoPediatrics reported a Q4 GAAP EPS of -$0.43, missing expectations by $0.09, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $61.6 million, a 16.9% year-over-year increase, surpassing market expectations by $0.33 million, demonstrating sustained demand in the pediatric orthopedic market and enhancing future growth potential.
- Future Outlook: OrthoPediatrics projects FY25 revenue of $236.1 million, reflecting a positive outlook for future markets, although current profitability issues suggest a need for improvement in earnings management.
- Market Reaction: Despite strong revenue growth, the decline in EPS may lead to negative short-term reactions from the market, prompting investors to monitor future measures for profitability improvement.
See More
OrthoPediatrics and iotaMotion Partner Receive FDA Clearance
- FDA Clearance Expansion: iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children aged four and older, significantly broadening access to robotic-assisted cochlear implantation and expected to enhance OrthoPediatrics' market share in the pediatric ENT sector.
- Deepening Strategic Partnership: The collaboration between OrthoPediatrics and iotaMotion aims to integrate advanced robotic technology into pediatrics, improving the efficiency and consistency of cochlear implant surgeries, thereby solidifying its leadership position in pediatric healthcare.
- First Adopting Hospital: Cincinnati Children's Hospital becomes the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S., marking widespread recognition of this technology in pediatrics and likely encouraging further hospital adoption.
- Broad Market Prospects: OrthoPediatrics plans to leverage this technology to expand its impact in pediatric care, supported by a capital-light business model and diverse revenue streams, addressing unmet pediatric needs effectively.
See More
OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products
New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.
Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.
Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.
Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.
See More
OrthoPediatrics Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: In Q1 2026, OrthoPediatrics reported worldwide revenue of $59.4 million, reflecting a 13% increase year-over-year, despite a temporary decline due to weather disruptions in January and February, with a rebound in March indicating resilient market demand.
- Improved Adjusted EBITDA: The adjusted EBITDA for the first quarter was $2.2 million, a substantial improvement from a loss of $0.4 million in Q1 2025, showcasing the company's significant enhancements in cost control and operational efficiency, which are expected to lay a solid foundation for future profitability.
- Optimized Financing Structure: On March 31, the company amended its existing credit agreement to add a $20 million delayed draw term loan facility, which will help maintain liquidity and avoid dilution, with interest payments only due until maturity in 2029.
- Upgraded 2026 Performance Outlook: Management raised the 2026 revenue guidance to a range of $263 million to $267 million, with an expected adjusted EBITDA of approximately $25 million, emphasizing the company's strategic positioning and market expansion potential within the innovation super cycle.
See More
OrthoPediatrics (KIDS) Q1 2026 Earnings Transcript
See More
OrthoPediatrics Reports Strong Q4 2025 Earnings with Positive Cash Flow
- Significant Revenue Growth: OrthoPediatrics reported worldwide revenue of $61.6 million for Q4 2025, reflecting a 17% year-over-year increase, with U.S. revenue at $48.6 million and international revenue at $13.0 million, demonstrating strong performance across trauma, deformity, and scoliosis segments, thereby solidifying its market position.
- First Positive Free Cash Flow: The company achieved $10 million in free cash flow during Q4 2025, marking its first quarter of positive cash flow in history, which indicates a significant improvement in operational efficiency and provides funding support for future investments and expansions.
- Optimistic 2026 Outlook: Management reiterated its revenue guidance for 2026 at $262 million to $266 million, projecting an annual growth rate of 11% to 13%, while also expecting approximately $25 million in adjusted EBITDA, reflecting confidence in sustained profitability and growth.
- Launch of Innovation Cycle: The company commenced what it believes to be the most substantial series of product launches in its history in 2025, including the 3P Hip and VerteGlide, which is expected to initiate a multi-year super cycle of product innovation, laying a foundation for future growth and expanding market share.
See More
OrthoPediatrics Q4 Earnings Report Analysis
- Earnings Performance: OrthoPediatrics reported a Q4 GAAP EPS of -$0.43, missing expectations by $0.09, indicating challenges in profitability that could affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $61.6 million, a 16.9% year-over-year increase, surpassing market expectations by $0.33 million, demonstrating sustained demand in the pediatric orthopedic market and enhancing future growth potential.
- Future Outlook: OrthoPediatrics projects FY25 revenue of $236.1 million, reflecting a positive outlook for future markets, although current profitability issues suggest a need for improvement in earnings management.
- Market Reaction: Despite strong revenue growth, the decline in EPS may lead to negative short-term reactions from the market, prompting investors to monitor future measures for profitability improvement.
See More
OrthoPediatrics and iotaMotion Partner Receive FDA Clearance
- FDA Clearance Expansion: iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children aged four and older, significantly broadening access to robotic-assisted cochlear implantation and expected to enhance OrthoPediatrics' market share in the pediatric ENT sector.
- Deepening Strategic Partnership: The collaboration between OrthoPediatrics and iotaMotion aims to integrate advanced robotic technology into pediatrics, improving the efficiency and consistency of cochlear implant surgeries, thereby solidifying its leadership position in pediatric healthcare.
- First Adopting Hospital: Cincinnati Children's Hospital becomes the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S., marking widespread recognition of this technology in pediatrics and likely encouraging further hospital adoption.
- Broad Market Prospects: OrthoPediatrics plans to leverage this technology to expand its impact in pediatric care, supported by a capital-light business model and diverse revenue streams, addressing unmet pediatric needs effectively.
See More
OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products
New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.
Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.
Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.
Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.
See More
